New Medicines, Novel Insights: Accelerating development of cell and gene therapies
Cell and gene therapies offer extraordinary hope to patients with advanced cancers and genetic diseases but pose unprecedented challenges for sponsors. In this report, Parexel experts share insights that can bring these complex treatments to market faster and more efficiently.
Related Insights
Report
New Medicines, Novel Insights: Advancing rare disease drug development
May 22, 2023
Report
New Medicines, Novel Insights: Achieving patient-guided drug development
Oct 30, 2023
Video
Part 2: Risk-based Quality Management Video (RBQM) Series
Nov 11, 2021
Video
The FDAs Race and Ethnic Diversity Plan Guidance: How prepared is your organization?
Feb 1, 2023
Video
Cell & Gene Therapies: A Regulatory Update
Jul 22, 2022
Podcast
Rare endpoints: Delivering on unmet patient needs
May 7, 2024
Blog
Accelerating Delivery and Patient Access to Rare Disease Treatments – Highlights from World Orphan Drug Congress
May 2, 2024
Article
Part 1 - Preparing for a Risk-Based Future: What ICH Revisions Mean for Clinical Trial Design and Conduct
Sep 14, 2021
Blog
Celebrating 40 Years of Rare Disease Progress: WODC Highlights
Jun 6, 2023
Blog
Adapting the validation process for PROs for rare diseases and other diseases with large unmet need and/or rapid progression
Apr 23, 2024
Blog
Including patients in DCT design
Sep 13, 2022
Video
How to transition existing trials under EU-CTR
Feb 1, 2023
Related Insights
Report
New Medicines, Novel Insights: Advancing rare disease drug development
May 22, 2023
Report
New Medicines, Novel Insights: Achieving patient-guided drug development
Oct 30, 2023
Video
Part 2: Risk-based Quality Management Video (RBQM) Series
Nov 11, 2021
Video
The FDAs Race and Ethnic Diversity Plan Guidance: How prepared is your organization?
Feb 1, 2023
Video
Cell & Gene Therapies: A Regulatory Update
Jul 22, 2022
Podcast
Rare endpoints: Delivering on unmet patient needs
May 7, 2024
Blog
Accelerating Delivery and Patient Access to Rare Disease Treatments – Highlights from World Orphan Drug Congress
May 2, 2024
Article
Part 1 - Preparing for a Risk-Based Future: What ICH Revisions Mean for Clinical Trial Design and Conduct
Sep 14, 2021
Blog
Celebrating 40 Years of Rare Disease Progress: WODC Highlights
Jun 6, 2023
Blog
Adapting the validation process for PROs for rare diseases and other diseases with large unmet need and/or rapid progression
Apr 23, 2024
Blog
Including patients in DCT design
Sep 13, 2022
Video
How to transition existing trials under EU-CTR
Feb 1, 2023